Name: Acrux (ACR) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

ACR

Pharmaceuticals, Biotechnology & Life Sciences

Acrux

Short interest: 0.21%; +0.20 pp 30d; as of 6 Dec 2024
Reported shorts: 611.8K
Shares on issue: 290.717M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Acrux

Acrux Limited is a leading Australian company in the pharmaceutical industry, specializing in the development and commercialization of topical and transdermal drug delivery systems. These innovative solutions are aimed at enhancing the efficiency and effectiveness of drug administration through the skin. With strong ties to scientific research and robust market distribution channels, Acrux positions itself as a pioneer in the transdermal patch market.

Company profile →

Acrux (ASX:ACR) has 0.21% of its shares on issue reported as short positions as of 6 Dec 2024, or about 611,822 shares. Over the past 30 days that figure has risen 0.20 percentage points, and over 90 days it has risen 0.20 percentage points. Its highest recorded short interest was 15.90% in July 2014. ACR is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads ACR today

Zanger BreakoutWatchScore 66rank 2 of 1942
CAN SLIMWatchScore 25rank 429 of 1541
Minervini Trend TemplateWatchScore 28rank 623 of 1716
Crowded-Short BreakoutWatchScore 32rank 118 of 1500
Quality compoundersWatchScore 25rank 511 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

ACR fundamentals

In the year to 30 Jun 2026, Acrux (ASX:ACR) recorded revenue of A$4.3M and a net loss after tax of A$604.0K. A year earlier it recorded revenue of A$1.2M and a net loss after tax of A$5.9M. Year-on-year growth: revenue +261.2% (FY). Net margin −14.1%, return on equity −48.5% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →